Kamada (KMDA) Return on Capital Employed (2018 - 2026)
Kamada's (KMDA) quarterly Return on Capital Employed came in at 5903.87% in Q1 2026, up 589349.0% YoY from N/an in Q1 2025, and up 2.95% on a QoQ basis from 5734.87% in Q4 2025.
Kamada (KMDA) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kamada (KMDA) has 9 years of Return on Capital Employed data on file, last reported at 5903.87% in Q1 2026.
- Quarterly Return on Capital Employed rose 589349.0% year-over-year to 5903.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5903.87% (up 589349.0% YoY) and the FY2025 annual result came in at 8.0%, up 161.0% from the prior year.
- Return on Capital Employed climbed to 5903.87% in Q1 2026, from 5734.87% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5903.87% in Q1 2026 to a low of 2.42% in Q2 2022.
- A 5-year average of 1372.51% and a median of 2.76% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 1245 bps — and 2026, when it surged 589349 bps.
- Tracing KMDA's Return on Capital Employed over 5 years: stood at 1.6% in 2022, then surged by 72 bps to 2.76% in 2023, then soared by 237 bps to 9.32% in 2024, then soared by 61417 bps to 5734.87% in 2025, then gained by 3 bps to 5903.87% in 2026.
- The last three Return on Capital Employed figures came in at 5903.87% (Q1 2026), 5734.87% (Q4 2025), and 5836.08% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Kamada | 461.75 Mn | 432.27 Mn | 22.47 Mn | 11.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.15% |
| Mar 31, 2026 | 5,903.87% |
| Dec 31, 2025 | 5,734.87% |
| Sep 30, 2025 | 5,836.08% |
| Jun 30, 2025 | 5,817.20% |
| Mar 31, 2025 | 10.38% |
| Dec 31, 2024 | 9.32% |
| Sep 30, 2024 | 7.02% |
| Jun 30, 2024 | 2.55% |
| Mar 31, 2024 | 2.55% |
| Dec 31, 2023 | 2.76% |
| Sep 30, 2023 | 2.77% |
| Jun 30, 2023 | 1.80% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | 1.60% |
| Sep 30, 2022 | 1.60% |
| Jun 30, 2022 | -2.42% |
| Mar 31, 2022 | -1.05% |
| Dec 31, 2021 | 0.20% |
| Sep 30, 2021 | 4.01% |